A practical field guide for orthopedic and spine devices: when post-market clinical follow-up is really required, which evidence route fits your device, and what to measure at each stage of implant follow-up.
Your PMCF plan is designed and defended by former Notified Body reviewers, starting with our orthopedics & spine lead.
Nikhil leads Eclevar's orthopedic and spine evidence programs. As a former TÜV SÜD reviewer, he designs PMCF and clinical evaluation strategies the way a Notified Body reads them: proportionate, traceable and defensible for Class III implants, from protocol through to CER update.
PMCF is not automatic paperwork. It is triggered by specific gaps in your clinical evidence. If one of these applies to your implant, a proportionate PMCF plan protects your CE mark; if none do, you can often justify a lighter route.
A new anatomical site, patient population or clinical claim not covered by existing data.
New material, coating, geometry or manufacturing process affecting performance or safety.
A more invasive procedure or higher anatomical risk than the equivalent device relied upon.
Wear, loosening, migration or fracture risks that only emerge over years of implantation.
Trends in complaints, vigilance data or the literature that need active confirmation.
Marketing based on a predicate device, where transferability must be demonstrated post-market.
Extending a system across sizes, populations or indications beyond the original evidence.
New benchmarks or competitor data that shift the acceptable benefit–risk threshold.
Most orthopedic PMCF plans combine two or three of these. The right mix depends on your device risk class, the questions left open by your CER, and how much long-term data your predicate already carries.
Controlled follow-up with predefined endpoints and timepoints, the strongest, most resource-intensive route for high-risk implants.
2–10 year observational collection through national joint or spine registries · the backbone of long-term orthopedic evidence.
Retrospective analysis of existing medical records to confirm real-world safety and revision rates at lower cost.
Predefined sampling of surgeons or patients (PROMs) for validated feedback on function and satisfaction.
Systematic analysis of published case series and comparable devices to close specific evidence gaps.
An integrated plan combining registry, survey and literature into one MDCG-aligned PMCF strategy.
A proportionate PMCF plan starts from the CER, not from a template. We map each residual claim and each risk to the lightest method that can actually answer it, so you are not running a prospective study to confirm something a registry already proves, or leaning on a survey where a Notified Body will expect radiographic endpoints.
The result is a plan that a reviewer reads as deliberate: every activity traces back to a specific gap, every endpoint updates the CER.
Implant evidence is a timeline, not a single readout. These are the endpoints reviewers expect to see mapped across the life of the device.
Eclevar manages RegenLab's PMCF program on chronic wound devices. This is a randomized study of 160 patients across 14 sites in 5 EU countries, covering both diabetic foot ulcer (DFU) and venous leg ulcer (VLU) indications. The partnership combines Eclevar's ISO 14155 clinical expertise with the Milo Studio platform to deliver post-market clinical follow-up evidence that supports both Notified Body scrutiny and reimbursement endpoints, from protocol design through to final study report.
"Eclevar, with its tailor-made approach and advanced Milo Studio platform, represents a major strategic asset."
Our joint whitepaper with BSI on building clinical evidence under the EU MDR.
Read the whitepaper →A forthcoming whitepaper by Dr Nikhil Khadabadi (Eclevar), in collaboration with TÜV SÜD.
Coming soon
A one-page decision aid for orthopedic and spine teams: PMCF triggers, evidence routes and the implant endpoint timeline, ready to bring to your next CER or Notified Body discussion.
Dr Mark Da Costa
Pierre-Marie Boutanquoi